|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01557660 |
|
Date of registration:
|
14/03/2012 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Inhaled Treprostinil for PAH: Open-label Extension
INTREPID - OL |
|
Scientific title:
|
Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study |
|
Date of first enrolment:
|
June 2012 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT01557660 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 3
|
|
|
Key inclusion & exclusion criteria
|
Participation and completion of all required visits for study RIN-PH-302.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pulmonary Arterial Hypertension
|
|
Intervention(s)
|
|
Drug: inhaled treprostinil
|
|
Primary Outcome(s)
|
|
Long term safety of inhaled treprostinil
[Time Frame: up to 5 years]
|
|
Secondary Outcome(s)
|
|
Six-minute walk distance
[Time Frame: up to 5 years]
|
|
Secondary ID(s)
|
|
RIN-PH-303
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|